Clinical Outcome between Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndrome and Diabetes
Background. The increased thrombotic risk in patients with acute coronary syndrome (ACS) and diabetes highlights the need for adequate antithrombotic protection. We aimed to compare the 6-month clinical outcomes between ticagrelor and clopidogrel in patients with ACS and diabetes. Methods and Result...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Cardiovascular Therapeutics |
| Online Access: | http://dx.doi.org/10.1155/2021/5546260 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832549172056686592 |
|---|---|
| author | Peixun He Xiaolin Luo Jiabei Li Yi Li Xiaozeng Wang Lan Huang Jun Jin Yaling Han |
| author_facet | Peixun He Xiaolin Luo Jiabei Li Yi Li Xiaozeng Wang Lan Huang Jun Jin Yaling Han |
| author_sort | Peixun He |
| collection | DOAJ |
| description | Background. The increased thrombotic risk in patients with acute coronary syndrome (ACS) and diabetes highlights the need for adequate antithrombotic protection. We aimed to compare the 6-month clinical outcomes between ticagrelor and clopidogrel in patients with ACS and diabetes. Methods and Results. The study was a single-center, prospective, randomized, open-label, blinded endpoint, and controlled registry trial. A total of 270 ACS patients with diabetes were randomly assigned in a 1 : 1 ratio to either the ticagrelor group or the clopidogrel group. Follow-up was performed for 6 months, and the data on efficacy outcomes and bleeding events were collected. At 6 months, complete follow-up data were available for 266 (98.5%) of 270 patients, and 4 were lost to follow-up. There was no significant difference in the survival rate of the effective endpoints between the ticagrelor group (n=133) and the clopidogrel group (n=133) (HR 0.83, 95% CI 0.44–1.56, p=0.561), but the incidence of bleeding events in the ticagrelor group was higher than that in the clopidogrel group (HR 1.76, 95% CI 1.00–3.10, p=0.049). Conclusion. Ticagrelor did not improve the composite of nonfatal MI, target vessel revascularization, rehospitalization, stroke, and death from any cause; however, it significantly increased the incidence of bleeding events defined by the Bleeding Academic Research Consortium (BARC) criteria in Chinese patients with ACS and diabetes during the 6-month follow-up compared with clopidogrel. |
| format | Article |
| id | doaj-art-7dc0eadde48742fc962454553a4b4fb4 |
| institution | Kabale University |
| issn | 1755-5914 1755-5922 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cardiovascular Therapeutics |
| spelling | doaj-art-7dc0eadde48742fc962454553a4b4fb42025-02-03T06:12:04ZengWileyCardiovascular Therapeutics1755-59141755-59222021-01-01202110.1155/2021/55462605546260Clinical Outcome between Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndrome and DiabetesPeixun He0Xiaolin Luo1Jiabei Li2Yi Li3Xiaozeng Wang4Lan Huang5Jun Jin6Yaling Han7Department of Cardiology, The Second Affiliated Hospital, Army Medical University, Chongqing, ChinaDepartment of Cardiology, The Second Affiliated Hospital, Army Medical University, Chongqing, ChinaDepartment of Cardiology, The Second Affiliated Hospital, Army Medical University, Chongqing, ChinaDepartment of Cardiology, General Hospital of Northern Theater Command, Shenyang, ChinaDepartment of Cardiology, General Hospital of Northern Theater Command, Shenyang, ChinaDepartment of Cardiology, The Second Affiliated Hospital, Army Medical University, Chongqing, ChinaDepartment of Cardiology, The Second Affiliated Hospital, Army Medical University, Chongqing, ChinaDepartment of Cardiology, General Hospital of Northern Theater Command, Shenyang, ChinaBackground. The increased thrombotic risk in patients with acute coronary syndrome (ACS) and diabetes highlights the need for adequate antithrombotic protection. We aimed to compare the 6-month clinical outcomes between ticagrelor and clopidogrel in patients with ACS and diabetes. Methods and Results. The study was a single-center, prospective, randomized, open-label, blinded endpoint, and controlled registry trial. A total of 270 ACS patients with diabetes were randomly assigned in a 1 : 1 ratio to either the ticagrelor group or the clopidogrel group. Follow-up was performed for 6 months, and the data on efficacy outcomes and bleeding events were collected. At 6 months, complete follow-up data were available for 266 (98.5%) of 270 patients, and 4 were lost to follow-up. There was no significant difference in the survival rate of the effective endpoints between the ticagrelor group (n=133) and the clopidogrel group (n=133) (HR 0.83, 95% CI 0.44–1.56, p=0.561), but the incidence of bleeding events in the ticagrelor group was higher than that in the clopidogrel group (HR 1.76, 95% CI 1.00–3.10, p=0.049). Conclusion. Ticagrelor did not improve the composite of nonfatal MI, target vessel revascularization, rehospitalization, stroke, and death from any cause; however, it significantly increased the incidence of bleeding events defined by the Bleeding Academic Research Consortium (BARC) criteria in Chinese patients with ACS and diabetes during the 6-month follow-up compared with clopidogrel.http://dx.doi.org/10.1155/2021/5546260 |
| spellingShingle | Peixun He Xiaolin Luo Jiabei Li Yi Li Xiaozeng Wang Lan Huang Jun Jin Yaling Han Clinical Outcome between Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndrome and Diabetes Cardiovascular Therapeutics |
| title | Clinical Outcome between Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndrome and Diabetes |
| title_full | Clinical Outcome between Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndrome and Diabetes |
| title_fullStr | Clinical Outcome between Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndrome and Diabetes |
| title_full_unstemmed | Clinical Outcome between Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndrome and Diabetes |
| title_short | Clinical Outcome between Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndrome and Diabetes |
| title_sort | clinical outcome between ticagrelor versus clopidogrel in patients with acute coronary syndrome and diabetes |
| url | http://dx.doi.org/10.1155/2021/5546260 |
| work_keys_str_mv | AT peixunhe clinicaloutcomebetweenticagrelorversusclopidogrelinpatientswithacutecoronarysyndromeanddiabetes AT xiaolinluo clinicaloutcomebetweenticagrelorversusclopidogrelinpatientswithacutecoronarysyndromeanddiabetes AT jiabeili clinicaloutcomebetweenticagrelorversusclopidogrelinpatientswithacutecoronarysyndromeanddiabetes AT yili clinicaloutcomebetweenticagrelorversusclopidogrelinpatientswithacutecoronarysyndromeanddiabetes AT xiaozengwang clinicaloutcomebetweenticagrelorversusclopidogrelinpatientswithacutecoronarysyndromeanddiabetes AT lanhuang clinicaloutcomebetweenticagrelorversusclopidogrelinpatientswithacutecoronarysyndromeanddiabetes AT junjin clinicaloutcomebetweenticagrelorversusclopidogrelinpatientswithacutecoronarysyndromeanddiabetes AT yalinghan clinicaloutcomebetweenticagrelorversusclopidogrelinpatientswithacutecoronarysyndromeanddiabetes |